Dibenzylxanthines as PPEPCK-M Inhibitors for Cancer Therapy

by Marc Aragó, Sergio Rodríguez-Arévalo, Petra Hyrossova, Juan Moreno, Sònia Abás, Agnès Figueras, Belén Pérez, Francesc Viñals, María Carmen Escolano, José Carlos Perales
Published 2019-08-01

Biological Evaluation of a Mitochondrial Phosphoenolpyruvate Carboxykinase Inhibitor

by Sergio Rodríguez-Arévalo, Sònia Abás, Marc Aragó, Juan Moreno-Felici, Petra Hyroššová, Jose Carlos Perales, Carles Galdeano, Tiziana Ginex, Francisco Javier Luque, Carmen Escolano
Published 2019-09-01

PEPCK-M recoups tumor cell anabolic potential in a PKC-ζ-dependent manner

by Petra Hyroššová, Marc Aragó, Juan Moreno-Felici, Xiarong Fu, Andrés Mendez-Lucas, Pablo M. García-Rovés, Shawn Burgess, Agnès Figueras, Francesc Viñals, Jose C. Perales
Published 2021-01-01

Pharmacology and preclinical validation of a novel anticancer compound targeting PEPCK-M

by Marc Aragó, Juan Moreno-Felici, Sonia Abás, Sergio Rodríguez-Arévalo, Petra Hyroššová, Agnes Figueras, Francesc Viñals, Belén Pérez, Maria I. Loza, Jose Brea, Pedro Latorre, Jose A. Carrodeguas, Pablo M. García-Rovés, Carlos Galdeano, Tiziana Ginex, Francisco J. Luque, Carmen Escolano, Jose C. Perales
Published 2020-01-01

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

by Álvaro Lahiguera, Petra Hyroššová, Agnès Figueras, Diana Garzón, Roger Moreno, Vanessa Soto‐Cerrato, Iain McNeish, Violeta Serra, Conxi Lazaro, Pilar Barretina, Joan Brunet, Javier Menéndez, Xavier Matias‐Guiu, August Vidal, Alberto Villanueva, Barbie Taylor‐Harding, Hisashi Tanaka, Sandra Orsulic, Alexandra Junza, Oscar Yanes, Cristina Muñoz‐Pinedo, Luís Palomero, Miquel Àngel Pujana, José Carlos Perales, Francesc Viñals
Published 2020-06-01